EcoDrugPlus

Phosphatidylinositol 3-Kinase Regulatory Subunit Gamma-Like

Ensembl ID : ENSAMXG00000039090
Gene Symbol: LOC103035767
2 Cross references
199 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha

Ensembl ID : ENSAMXG00000009771
Gene Symbol: PIK3CA
3 Cross references
200 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSAMXG00000001526
Gene Symbol: PIK3CB
3 Cross references
218 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSAMXG00000013276
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSAMXG00000004209
Gene Symbol: PIK3CG
3 Cross references
216 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSAMXG00000004012
Gene Symbol: PDE10A
1 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSAMXG00000004292
Gene Symbol: PDE3A
3 Cross references
203 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSAMXG00000007860
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSAMXG00000031477
Gene Symbol: PDE4A
1 Cross references
187 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSAMXG00000010617
Gene Symbol: PDE4B
1 Cross references
229 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSAMXG00000040783
Gene Symbol: PDE4B
3 Cross references
224 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSAMXG00000029287
Gene Symbol: PDE4D
1 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).